International Journal of Cancer and Biomedical Research最新文献

{"title":"Parathyroid Hormone as a Predictor of Post Total Thyroidectomy Parathyroid Gland Injury","authors":"Mohamed E. Abd-Elaziz, A. Essawy, H. Wageh, Noha S. Khalifa, Mohamed Zydan","doi":"10.21608/jcbr.2021.60086.1140","DOIUrl":"https://doi.org/10.21608/jcbr.2021.60086.1140","url":null,"abstract":"Background: Post-thyroidectomy hypocalcaemia is one of the most prevalent morbidities. Serum parathormone hormone (PTH) levels before and after the operation have been an area of high interest for detecting the risk of postoperative hypocalcaemia. Aim: This study was conducted to determine the accuracy of perioperative parathormone hormone assessment as a predictor of parathyroid gland injury in total thyroidectomy operations. Methods: Fifty patients presented with goiter indicated for total thyroidectomy operation were evaluated and operated. Routine preoperative labs with measurement of the parathormone hormonal level, thyroid profile, and serum calcium (Ca) were done. Results: The level of postoperative PTH was lower in patients with post-operative manifestations of hypocalcaemia than those without (6.3 ± 5.1 vs. 24.8 ± 6.7), with a 78.9% drop in PTH from the preoperative level in the hypocalcaemia group versus 56.1% drop in the normocalcemia group (P < 0.0001). Percentage changes in PTH had good discriminative power, AUC=0.840 (95% CI: 0.648-1.000), p=0.002. Conclusion: postoperative PTH levels can be a good predictor of hypocalcemia in total thyroidectomies. Patients with a greater than 64.8% decrease in PTH levels were significantly more likely to develop hypocalcemia.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115627800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD44 and p53 co-expression in high grade, muscle invasive bladder urothelial carcinoma with and without schistosomiasis","authors":"Rehab Sharaf El Deen, O. Sayed, Wesam I Moustafa","doi":"10.21608/jcbr.2021.39890.1064","DOIUrl":"https://doi.org/10.21608/jcbr.2021.39890.1064","url":null,"abstract":"Background & Objectives: In Egypt, most patients diagnosed as urothelial carcinoma (UC) have high grade and muscle-invasive tumors that are commonly associated with schistosomal cystitis. CD44 and p53 may represent potential targets for anticancer treatment. We aimed to assess the expression of CD44 & p53 and to determine their association in high grade, muscle-invasive tumors. Materials and Methods: Thirty four cystectomy cases with high-grade muscle-invasive UC were collected. Sections were stained for CD44 and p53 taking 10% and 20% positivity as cutoff values, respectively. Results: Median age was 60.5 years. Male/female ratio was 4:1.Fourteen cases were T2, 12 were T3, and 8 were T4. Nodal metastasis was evident in 8 cases. Conventional histology was seen in 38%, followed by squamous differentiation in 24%. Twenty patients had bilharzial cystitis. CD44 was positive in 8.8% of cases whereas p53 immunopositivity was noted in 76.5%. CD44 and p53 expression had no statistical association with stage (p =0.52 and 0.97) or bilharzial infestation (p=0.34 and 0.16). There was no significant association between CD44 expression and that of p53, p= 0.06. Conclusion: High-grade muscle-invasive Schistosomal associated urothelial carcinomas are common, but with limited CD44 and p53 co-expression.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132479504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wilms' tumor may be a rare presentation of ovarian neoplasms in girls","authors":"Suzy Abdelmabood, Heba Sheta, Sherif Abdelmaksoud, B. Refky, N. A. Touk, Dina Harb, A. Darwish","doi":"10.21608/jcbr.2021.49736.1094","DOIUrl":"https://doi.org/10.21608/jcbr.2021.49736.1094","url":null,"abstract":"Extrarenal Wilms' tumor is a rare malignant disorder. It represents 0.5-1% of Wilms' tumor. Management for ERWT is challenging regarding its pathological diagnosis, staging, treatment and prognosis. Here we report a 4 years old girl, presented with huge pelvi abdominal mass originating from the left ovary which was seen by radiologic assessment as a large lobulated heterogeneously enhancing mixed solid and cystic retroperitoneal mass away from both kidneys, occupying most of the abdomen with pelvic extension; it was displacing bowel loops and pancreas, measuring 13 x 15 x 16 cm without evidence of enlarged lymphadenopathy. The mass was diagnosed postoperatively as an extrarenal Wilms' tumor proved by immunohistochemical staining for Wilms' Tumor1 (WT1) with the negative reaction for other markers that exclude other diagnostic possibilities. The patient had an aggressive presentation and advanced disease. The diagnosis was difficult due to the lack of specific radiologic stigmata and aberrant origin. She was treated with aggressive chemotherapy to suit the advanced stage of her disease and unfavorable histology pattern.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"314 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132049138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term survival outcome of childhood acute lymphoblastic leukemia treated with modified TXIIIB protocol at South Egypt Cancer Institute","authors":"A. Shibl, H. Sayed, A. Ali, D. Mahmoud, Omnia N. Abdelhamid","doi":"10.21608/jcbr.2021.59346.1126","DOIUrl":"https://doi.org/10.21608/jcbr.2021.59346.1126","url":null,"abstract":"Background: The survival of children with acute lymphoblastic leukemia (ALL) has greatly improved in recent decades. Aim: We aimed at evaluating the outcome of children with ALL and their prognostic factors. Materials & Methods: A prospective study included 200 newly diagnosed pediatric ALL patients from 2009 to 2017. All patients were treated according to the modified total therapy study XIIIB for higher risk ALL adopted from St. Jude Children's Research hospital (SJCRH), USA. Results: Favorable age (< 10 y) and total leucocytic count (TLC) (≥ 50x109/L) occurred in 75% and 69%, respectively. B-precursor ALL represented 82.5%. Central nervous system (CNS) involvement occurred in 4.5%. High-risk patients represented 47%. Complete remission was achieved in 92.5% and was significantly affected by the early morphologic response of BM d15, while it wasn’t related to the phenotype. Eight- year overall survival, disease-free survival, and event-free survival were 77 ± 3%, 70 ± 4%, and 66 ± 3%, respectively. Adverse events included induction deaths (4.5 %(, refractory leukemia (3%), relapse (23.2%), secondary AML (0.5%), and deaths in remission (3.5%). By multivariate analysis, unfavorable age group ≥ 10 years, hyperleukocytosis, and patients with slow early response were the only ones associated with unfavorable impact on the outcome. There was statistical significant difference between standard and high risk for B-precursor ALL but not for T- precursor ALL. Conclusion: We concluded that treating children with ALL through modified TXIIIB protocol improved the survival at our institute than previous and the early response to treatment has a strong implication on the outcome.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"334 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133232089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of ALK gene rearrangement and its association with survival rate among Upper Egypt Non-Small cell lung cancer patients","authors":"Marwa I Abdelgawad, Heba Saadeldein, Ebtessam Elgizawy, Ahmed Roshdi, A. Badran, Marwa Nofal, Sahar A. Elgammal, K. Nasif, E. Mosaad","doi":"10.21608/jcbr.2021.48701.1091","DOIUrl":"https://doi.org/10.21608/jcbr.2021.48701.1091","url":null,"abstract":"Background: Anaplastic Lymphoma Kinase(ALK)gene rearrangement shows ethnic variations worldwide. There isn’t a population-based study measuring its prevalence among the Egyptian population till now. Aim: To measure ALK gene rearrangement prevalence correlated with survival rates among a sample of Upper Egypt Non-Small Cell Lung Cancer (NSCLC) patients. Patients and Methods: The study included twenty-six NSCLC patients. 21 of them were males and the rest were females, the enrolled patients had a median age of 60 years. 8 presented with pleural effusion, while 4 showed brain metastases, and 10 had liver metastases. Most of the cases were given a diagnosis with adenocarcinoma, squamous cell carcinoma (14, 6 cases, respectively), and the rest were given a diagnosis with undifferentiated carcinoma. Fluorescence Insitu Hybridization (FISH) technique was used for detection of rearranged ALK gene from FFEP Tissue Sections. Vysis ALK Break Apart FISH Probe Kit was used, it’s composed of two probes green-labeled one to bind to the 5′ end of the ALK gene, and another orange labeled one to bind to the 3′ end. Tumor cells with 15 % or more separate green 5′ and red 3′ signals or isolated red 3′ signals were considered positive for the rearranged ALK gene, while cells with yellowish signals (representing overlapped signals between green and red probes) were considered negative for ALK gene rearrangement. A fluorescence microscope supplied with a Leica CCD camera was used to detect clinicopathological characteristics of rearranged ALK gene, image processing was done using an imaging system and software. Results: Patients were followed up for 63 months, 15 of them were positive for the rearranged ALK gene. All patients were treated with chemotherapy and they had different objective response rates (ORR), ALK+ve cohort 73.3% (PR:3, SD:8), ALK–ve cohort 100% (PR:6, SD:5). The overall survival rate (OSR) was 51,6%, and two- year progression-free survival rate (PFSR) was 68,8%. Univariate analysis was done between ALK+ve / ALK–ve for different risk groups (age, gender, histological subtype, the site of metastasis, and grade). Patients with adenocarcinoma showed better OSR than those with squamous cell carcinoma, PConclusions: Patients with ALK gene rearrangement are resistant to chemotherapy, so they should be directed for individualized treatment, the prevalence of ALK+ve patients could be more than expected among the Egyptian population. further confirmation is required through multiple center population-based studies. Policymakers are invited for validating central laboratory, they are also recommended to enhance accessibility for diagnostic facilities and services, and adopting inhibitors of tyrosine kinase (TKI) as a new effective treatment strategy for NSCLC cases.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116912663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Trophoblastic Cell Surface Protein 2 (Trop2) Expression in Breast Cancer and Relation to Microvascular Density","authors":"A. Amer, S. Darwish, F. Ibrahim","doi":"10.21608/jcbr.2021.68609.1189","DOIUrl":"https://doi.org/10.21608/jcbr.2021.68609.1189","url":null,"abstract":"Background: The expression of trophoblastic cell surface protein 2 (Trop2) has been correlated with aggressive behavior in multiple malignant neoplasms. Moreover, it is a promising therapeutic target for several malignancies. However, data on the prognostic significance of Trop2 in breast cancer is insufficient. The current work aimed to study the prognostic significance of Trop2 expression in breast cancer and its correlation with microvascular density (MVD). Patients and Methods: Immunohistochemical expression of Trop2 was assessed in 70 cases of breast cancer and its relation to clinicopathological parameters, MVD (as assessed by CD34 immunostaining) and patient’s survival was evaluated. Results: High Trop2 expression was detected in 44 cases (62.9%) of the studied cases. The expression of Trop2 was significantly related to tumor size, lymph node stage, lymphovascular invasion, tumor grade and high Ki67 index (P<0.05).   Moreover, the expression of Trop2 was significantly higher in triple-negative breast carcinoma (TNBC) than other molecular subtypes (P=0.015). Additionally, Trop2 expression was significantly correlated to MVD (r= 0.845). Both overall survival and disease-free survival were significantly shorter in the high Trop2 group than low Trop2 group (P=0.008, 0.021), respectively.  Conclusion: Trop2 can be considered as a poor prognostic marker and potential therapeutic target for breast cancer, mainly the triple-negative subtype. Since Trop2 expression was significantly correlated to MVD, we speculate that enhancement of angiogenesis could be one of the mechanisms involved in Trop2 induced tumor invasion and metastasis.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115965176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Annual International Conference of the Egyptian Association for Cancer Research (EACR): Anti-Cancer Drug Discovery","authors":"M. Salem","doi":"10.21608/JCBR.2021.76821.1220","DOIUrl":"https://doi.org/10.21608/JCBR.2021.76821.1220","url":null,"abstract":"The future depends on the welfare of human beings by providing better health through research and technology. Biomedical research is of extreme importance to exploring and finding the human needs in particular new therapies for illnesses such as cancer. Indeed, cancer represents a global medical and economical challenge since it is a burden on the patients, families, physicians, and the government. Given the resistance of cancer cells to chemotherapy, it is of paramount importance for scientists to work on the discovery and development of new drugs that can reach the clinical market. As such, the Egyptian Association for Cancer Research (EACR) successfully organized its annual international conference under the title of “Anti-Cancer Drug Discovery (ACDD-2019) which was held from 21-22 April, 2019 at Tanta University convention Center, Tanta University, Tanta City, Egypt. ACDD-2019 (http://acdd.tanta.edu.eg/) represented an outstanding opportunity for sharing thoughts and idea for research from USA, China, Japan, KSA and other countries with the main goal to come up with the most effective translational anti-cancer agents. The conference included 3 main sessions on day 1 and 8 sessions on day 2. Day 1 included 13 keynote speakers covering different subjects in anti-cancer drug discovery and development including approached based on nanoparticles, gene therapy, immunotherapy and natural and synthetic compounds. Day 2 focused mainly on 5 topics including: 1) the roles of center of excellence of scientific research in drug discovery, 2) parasite and marine compounds and cancer, 3) natural and synthetic anti-cancer drugs, 4) molecular oncology and cancer stem cells, and 5) cancer immunology and immunotherapy. As the president of EACR and Chairman of ACDD-2019, thank you to all who have contributed to this great work.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124211927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Annual International Conference of the Egyptian Association for Cancer Research: Anti-Cancer Drug Discovery (ACDD-2019)","authors":"M. Salem","doi":"10.21608/JCBR.2021.84285.1218","DOIUrl":"https://doi.org/10.21608/JCBR.2021.84285.1218","url":null,"abstract":"Drug discovery and development together are the complete practice of identifying a new drug and passing it to market. It covers all areas of cancer biology, from cell signaling pathways to tumor hypoxia and from angiogenesis to cell death pathways. The Egyptian Association for Cancer Research (EACR) successfully organized its annual international conference under the theme of “Anti-Cancer Drug Discovery, 21-22 April 2019 at Tanta University convention Center, Egypt. ACDD-2019 was an excellent opportunity to gather national researchers and international researchers from the USA, China, Japan, KSA, and other countries to share their interest in drug discovery and development. The conference included 3 main sessions on day 1 and 8 sessions on day 2. Day 1 included 13 keynote speakers covering different subjects in anti-cancer drug discovery and based on nanoparticles, gene therapy, immunotherapy, and natural and synthetic compounds. Day 2 focused on the roles of the center of excellence of scientific research in drug discovery, parasite and marine compounds and cancer, natural and synthetic anti-cancer drugs, molecular oncology and cancer stem cells, and cancer immunology and immunotherapy. About 600 participants attended the conference including undergraduate and postgraduate students as well as faculty members from different colleges, universities, and research centers in Egypt. ACDD-2019 (http://acdd.tanta.edu.eg/) represented an outstanding opportunity for sharing thoughts and ideas for collaborative research in anti-cancer drug discovery and development from chemical synthesis to the clinic.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127994297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study","authors":"N. El-Anwar, Reham El Nemr","doi":"10.21608/jcbr.2021.56525.1108","DOIUrl":"https://doi.org/10.21608/jcbr.2021.56525.1108","url":null,"abstract":"max 250 words, single paragraph): The abstract should be complete and understandable without citation, references, table, or figure. Use structured abstract: Background, Aim, Materials & Methods, Results and Conclusion. The context and the rationale of the study are presented succinctly to support the objectives. The experimental methods and main results are summarized but should not be overburdened by numerical values or probability values. The abstract ends with a short and clear conclusion.","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115728802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of pyruvate kinase M2 (PKM2) and epidermal growth factor receptor (EGFR) expression and their clinicopathologic significance in bladder urothelial carcinoma","authors":"Passant A. El-Sheikh, M. Shamloula, A. Atef, Dina A Elguindy","doi":"10.21608/JCBR.2021.63224.1177","DOIUrl":"https://doi.org/10.21608/JCBR.2021.63224.1177","url":null,"abstract":"","PeriodicalId":428417,"journal":{"name":"International Journal of Cancer and Biomedical Research","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116514722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}